Evidence map›Paper›PMID 38264044›Full record

ReviewFrontiers in medicine2023

Potential therapeutic target for polysaccharide inhibition of colon cancer progression.

Jiawei Fan, Jianshu Zhu, He Zhu, Yinmeng Zhang, Hong Xu

Abstract readReview
In one paragraph

Review in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Degraded sulfated galactan derived fromMolecular medicine reports · 2026
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Polysaccharides fromNutrients · 2025
    Review
  10. Article
  11. Article
  12. Review
  13. AcetylatedFrontiers in oncology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jiawei FanDepartment of Gastroenterology, The First Hospital of Jilin University, Changchun, China.
Jianshu ZhuDepartment of Spine Surgery, The First Hospital of Jilin University, Changchun, China.
He ZhuDepartment of Gastroenterology, The First Hospital of Jilin University, Changchun, China.
Yinmeng ZhangDepartment of Gastroenterology, The First Hospital of Jilin University, Changchun, China.
Hong XuDepartment of Gastroenterology, The First Hospital of Jilin University, Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, colon cancer has become one of the most common malignant tumors worldwide, posing a great threat to human health. Studies have shown that natural polysaccharides have rich biological activities and medicinal value, such as anti-inflammatory, anti-cancer, anti-oxidation, and immune-enhancing effects, especially with potential anti-colon cancer mechanisms. Natural polysaccharides can not only protect and enhance the homeostasis of the intestinal environment but also exert a direct inhibition effect on cancer cells, making it a promising strategy for treating colon cancer. Preliminary clinical experiments have demonstrated that oral administration of low and high doses of citrus pectin polysaccharides can reduce tumor volume in mice by 38% (

Indexed as

apoptosiscolon cancerimmunityintestinal microbiotapolysaccharide

Identifiers

PMID38264044
PMCPMC10804854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.